Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular ...

Ocugen, Inc. (OCGN) announced the European Medicines Agency has granted orphan medicinal product designation for OCU410ST for the ...

Clinuvel Pharmaceuticals (ASX:CUV) has entered discussions with the European Medicines Agency to increase the recommended ...

A UK policy conference heard a clarion call for clarity and recognizing shared interests – from a regulator at the interface ...

Following a turbulent period marked by Brexit and the pandemic, Ben Hargreaves finds the agency aiming to streamline ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Clinuvel Pharmaceuticals is in advanced discussions with the ...

The upcoming Clinical Trials Supply and Outsourcing in Clinical Trials East Asia conferences will host discussions on supply ...

In this Science segment, we examine the European Medicines Agency's recent decision to recommend granting marketing authorization for the anti-Alzheimer's drug lecanemab. This follows an earlier ...

The EMA recommended that NUZ-001, formerly monepantel, be granted orphan medicinal product designation to treat ALS in Europe ...

It also has a marketing application to the European Medicines Agency, with a decision expected in 2025. BridgeBio has granted ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

Bavarian Nordic, with a diverse vaccine portfolio and $340 million in contracts for 2025, offers growth potential for ...